Should You Buy MacroGenics Inc (MGNX) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
MGNX is not a good buy right now for an impatient investor. The stock just spiked into nearby resistance (around 1.93–1.93) with an overbought short-term RSI and immediate post-market weakness, while fundamentals in 2025/Q3 deteriorated sharply. Momentum is positive, but the entry here is unfavorable unless it cleanly breaks above ~2.01 or pulls back toward support.
Technical Analysis
Trend/momentum: Bullish short-to-long moving average stack (SMA_5 > SMA_20 > SMA_200) plus a MACD histogram above zero and expanding suggests the uptrend is intact. However, RSI_6 at ~76.5 signals an overbought/extended condition after the +7.22% move. Levels: Pivot ~1.791. Immediate resistance is R1 ~1.926 (price closed ~1.893 and is hovering near this zone); next resistance R2 ~2.01. Supports are S1 ~1.655 and S2 ~1.571. With price pressing into R1 and RSI elevated, near-term risk skews to a pullback/mean reversion before a more attractive entry.
Analyst Ratings and Price Target Trends
No analyst rating or price-target change data was provided, so a recent trend in Wall Street ratings/targets cannot be assessed here. With the available data, the main 'pro' case would be technical momentum and bullish options skew; the main 'con' case is the sharp YoY financial deterioration and the stock being extended into resistance.
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3 USD with a low forecast of 2 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast MGNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGNX is 3 USD with a low forecast of 2 USD and a high forecast of 4 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 1.800
Current: 1.800
